Chloë Marden

547 total citations
13 papers, 444 citations indexed

About

Chloë Marden is a scholar working on Immunology, Molecular Biology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Chloë Marden has authored 13 papers receiving a total of 444 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Immunology, 6 papers in Molecular Biology and 3 papers in Cellular and Molecular Neuroscience. Recurrent topics in Chloë Marden's work include Immune Cell Function and Interaction (5 papers), CAR-T cell therapy research (2 papers) and Neutrophil, Myeloperoxidase and Oxidative Mechanisms (2 papers). Chloë Marden is often cited by papers focused on Immune Cell Function and Interaction (5 papers), CAR-T cell therapy research (2 papers) and Neutrophil, Myeloperoxidase and Oxidative Mechanisms (2 papers). Chloë Marden collaborates with scholars based in United Kingdom, United States and Italy. Chloë Marden's co-authors include Janet North, Mark W. Lowdell, Marcus Rattray, John V. Priestley, Dawn Savery, Sharon Averill, Juan J. López Costa, Robert J. Anderson, Christopher C. Benz and Gary K. Scott and has published in prestigious journals such as Blood, The Journal of Immunology and PLoS ONE.

In The Last Decade

Chloë Marden

13 papers receiving 435 citations

Peers

Chloë Marden
T Sarr United States
Amelia Fernandez‐Martin Spain
Taofang Hu United States
Andreas Pelz Germany
Tomasz Sobocki United States
Kiyomitsu Shoudai Japan
Kathy H. Katz United States
Dominique Bollino United States
Keith A. Kelley United States
McKale R. Montgomery United States
T Sarr United States
Chloë Marden
Citations per year, relative to Chloë Marden Chloë Marden (= 1×) peers T Sarr

Countries citing papers authored by Chloë Marden

Since Specialization
Citations

This map shows the geographic impact of Chloë Marden's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chloë Marden with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chloë Marden more than expected).

Fields of papers citing papers by Chloë Marden

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chloë Marden. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chloë Marden. The network helps show where Chloë Marden may publish in the future.

Co-authorship network of co-authors of Chloë Marden

This figure shows the co-authorship network connecting the top 25 collaborators of Chloë Marden. A scholar is included among the top collaborators of Chloë Marden based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chloë Marden. Chloë Marden is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Kottaridis, Panagiotis, Janet North, Chloë Marden, et al.. (2015). Two-Stage Priming of Allogeneic Natural Killer Cells for the Treatment of Patients with Acute Myeloid Leukemia: A Phase I Trial. PLoS ONE. 10(6). e0123416–e0123416. 49 indexed citations
2.
Govoni, Kristen E, L. R. Donahue, Chloë Marden, & Sneha Mohan. (2008). Complex genetic regulation of bone mineral density and insulin-like growth factor-I in C57BL/6J-Chr #A/J/NaJ chromosome substitution strains. Physiological Genomics. 35(2). 159–164. 3 indexed citations
3.
North, Janet, et al.. (2007). Tumor-Primed Human Natural Killer Cells Lyse NK-Resistant Tumor Targets: Evidence of a Two-Stage Process in Resting NK Cell Activation. The Journal of Immunology. 178(1). 85–94. 81 indexed citations
4.
North, Janet, Chloë Marden, R. Malayeri, et al.. (2005). Ligation of CD8α on human natural killer cells prevents activation‐induced apoptosis and enhances cytolytic activity. Immunology. 116(3). 354–361. 87 indexed citations
5.
Boyton, Rosemary J., et al.. (2005). Stat4-null non-obese diabetic mice: protection from diabetes and experimental allergic encephalomyelitis, but with concomitant epitope spread. International Immunology. 17(9). 1157–1165. 22 indexed citations
6.
Marden, Chloë, et al.. (2005). CD69 Is Required for Activated NK Cell-Mediated Killing of Resistant Targets.. Blood. 106(11). 3322–3322. 12 indexed citations
7.
Marden, Chloë, Deborah Cunninghame Graham, Adrian J. Thrasher, & Colin Casimir. (2003). A functional ISRE is required for myeloid transcription of the p47phox gene. Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression. 1630(2-3). 117–122. 1 indexed citations
8.
Marden, Chloë, et al.. (2003). Differentiation-dependent up-regulation of p47phox gene transcription is associated with changes in PU.1 phosphorylation and increased binding affinity. Biochemical and Biophysical Research Communications. 305(1). 193–202. 9 indexed citations
9.
Scott, Gary K., et al.. (2002). Transcriptional repression of ErbB2 by histone deacetylase inhibitors detected by a genomically integrated ErbB2 promoter-reporting cell screen.. Molecular Cancer Therapeutics. 1(6). 385–92. 55 indexed citations
10.
11.
Marden, Chloë, et al.. (1995). Analysis of the Neuronal Promoter of the Rat Aromatic l‐Amino Acid Decarboxylase Gene. Journal of Neurochemistry. 65(5). 1944–1954. 10 indexed citations
12.
Rattray, Marcus, Glen Wotherspoon, Dawn Savery, et al.. (1994). Chronic D-fenfluramine decreases serotonin transporter messenger RNA expression in dorsal raphe nucleus. European Journal of Pharmacology Molecular Pharmacology. 268(3). 439–442. 25 indexed citations
13.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by T Sarr Breakdown of academic impact, for papers by Amelia Fernandez‐Martin Breakdown of academic impact, for papers by Taofang Hu Breakdown of academic impact, for papers by Andreas Pelz Breakdown of academic impact, for papers by Tomasz Sobocki Breakdown of academic impact, for papers by Kiyomitsu Shoudai Breakdown of academic impact, for papers by Kathy H. Katz Breakdown of academic impact, for papers by Dominique Bollino Breakdown of academic impact, for papers by Keith A. Kelley Breakdown of academic impact, for papers by McKale R. Montgomery
Rankless by CCL
2026